Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Mayo Clinic to deploy and test Microsoft generative AI tools

    September 29, 2023

    Mylab Discovery Solutions introduces MyNeoShield for NBS

    September 28, 2023

    Celebrating World Pharmacists Day: Honoring unsung healthcare heroes

    September 27, 2023
    Facebook Twitter Instagram
    Your Healthtech
    • Health

      Mayo Clinic to deploy and test Microsoft generative AI tools

      September 29, 2023

      Mylab Discovery Solutions introduces MyNeoShield for NBS

      September 28, 2023

      Celebrating World Pharmacists Day: Honoring unsung healthcare heroes

      September 27, 2023

      Fortis Healthcare gains on plans to acquire Kolkata-based realty firm

      September 26, 2023

      Johnson & Johnson Vision introduces new procedure for patients with myopia

      September 25, 2023
    Your Healthtech
    Home»Health»Progress Flickers in Women’s Healthcare as Femtech Builds Traction
    Health

    Progress Flickers in Women’s Healthcare as Femtech Builds Traction

    yourhealthtechBy yourhealthtechDecember 6, 2022Updated:December 6, 2022No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Celmatix Founder and CEO Piraye Yurttas Beim, Ph.D/courtesy of Celmatix

    The introduction of the birth control pill in 1960 was arguably the last major advancement in a segment of the biopharma industry now known as femtech. That is changing now, as new companies form around de novo innovations that promise important advances for women’s healthcare.

    Many of these advances are still in preclinical development, but Global Market Insights predicts the worldwide market for therapeutics designed specifically for conditions and diseases that affect only (or mainly) women will exceed $65 billion by 2027.

    Celmatix: Ovarian Health, The complexities of the female body extend beyond reproduction. “The ovary sits at the center of not only the reproductive axis, but also the endocrine axis and the metabolic axis,” Piraye Yurttas Beim, Ph.D., founder and CEO of Celmatix, told BioSpace.

    Celmatix is developing an anti-mullerian hormone receptor 2 (AMHR2) agonist that regulates the entire 300-day process of follicular genesis. In contrast, current technology regulates estrogen and progesterone, and only affects the last 30 days of the follicles’ function.

    Anti-mullerian hormone (AMH) is the master regulator that determines the differing rates of decline of the ovary’s various functions. It signals through AMHR2, which is primarily found on ovarian cells.

    The AMHR2 agonist is designed initially for chemotherapy-induced ovarian failure. After about six weeks of chemotherapy, the cells that make AMH undergo apoptosis.

    At that point, “There’s nothing to keep the eggs and follicles in check,” Beim explained. As a result, the follicles are activated early. Consequently, the timeline (to menopause) that normally winds down from birth to about age 50, accelerates.

    “For every month on very high dose chemotherapy, you lose a year and a half of your timeline to menopause. Obviously, that has implications for fertility, but…these women are [also] at significantly increased risk of acquiring diseases of aging earlier in life.”

    When ovaries fail to function early in life, uterine fibroids, endometriosis, polycystic ovary syndrome (PCOS), infertility and early menopause may develop.

    “PCOS, for example, is a significant risk factor for mental health issues, diabetes and insulin resistance, metabolic disorder and obesity, heart disease, certain types of cancers and infertility,” Beim said. “It is niched as a reproductive condition, even though it is actually a significant metabolic and endocrine disorder.”

    Another example is endometriosis, an inflammatory disorder that increases a woman’s later risk of heart disease and stroke.

    Celmatix’s recombinant, biologically active AMH compound is being designed to add back an activity that’s missing from the body, Beim said. It’s been shown to protect the ovary in animal models that were exposed to chemotherapy. “You can’t experimentally differentiate between the ovaries that were exposed to chemotherapy and those that weren’t,” she noted.

    “The end of ovarian function during the menopause transition is the single biggest accelerant of the disease of aging for women,” Beim said. Therefore, “Celmatix is developing drugs to optimize the function of organs that are unique to women. This isn’t repurposing something…or targeting estrogen in yet another way. This is doing something fundamentally different.”

    This AMHR2 agonist has the potential to evolve as a broad platform. Additional pipeline programs will be announced in the coming year.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleNew Zealand Launches Inquiry Into Its Coronavirus Response
    Next Article Tridemic’ overwhelms Canadian health care system; here’s all you need to know
    yourhealthtech
    • Website

    Related Posts

    Mayo Clinic to deploy and test Microsoft generative AI tools

    September 29, 2023

    Mylab Discovery Solutions introduces MyNeoShield for NBS

    September 28, 2023

    Celebrating World Pharmacists Day: Honoring unsung healthcare heroes

    September 27, 2023

    Fortis Healthcare gains on plans to acquire Kolkata-based realty firm

    September 26, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fintech
    • Your Revenue
    • Your Bio Tech
    • Your Info Tech
    • Your POS Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.